[Pharmacologic analysis of the participation of endogenous noradrenaline in the retrograde development of neurogenic gastric dystrophy].
D000577:Amides / Q000627:therapeutic use; D000818:Animals; D001535:Benactyzine / Q000627:therapeutic use*; D001949:Bretylium Compounds / Q000627:therapeutic use*; D003998:Dicarboxylic Acids / Q000627:therapeutic use; D004558:Electric Stimulation; D005753:Gastric Mucosa / Q000378:metabolism*; D006584:Hexamethonium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007093:Imidazoles / Q000627:therapeutic use*; D007103:Immobilization; D008297:Male; D009638:Norepinephrine / Q000378:metabolism*; D009963:Orotic Acid / Q000627:therapeutic use*; D010643:Phenoxybenzamine / Q000494:pharmacology*; D051381:Rats; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D013272:Stomach Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism
D000577:Amides; D001949:Bretylium Compounds; D003998:Dicarboxylic Acids; D006584:Hexamethonium Compounds; D007093:Imidazoles; D010643:Phenoxybenzamine; D001535:Benactyzine; D009963:Orotic Acid; D009638:Norepinephrine
Farmakologicheskiĭ analiz uchastiia éndogennogo noradrenalina v obratnom razvitii neĭrogennoĭ distrofii zheludka.